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Disruption of Amino Acid
Homeostasis by Novel ASCT2
Inhibitors Involves Multiple Targets
Angelika Bröer, Stephen Fairweather and Stefan Bröer*
Research School of Biology, Australian National University, Canberra, ACT, Australia
The glutamine transporter ASCT2 (SLC1A5) is actively investigated as an oncological
target, but the field lacks efficient ASCT2 inhibitors. A new group of ASCT2 inhibitors,
2-amino-4-bis(aryloxybenzyl)aminobutanoic acids (AABA), were developed recently and
shown to suppress tumor growth in preclinical in vivo models. To test its specificity,
we deleted ASCT2 in two human cancer cell lines. Surprisingly, growth of parental and
ASCT2-knockout cells was equally sensitive to AABA compounds. AABA compounds
inhibited glutamine transport in cells lacking ASCT2, but not in parental cells. Deletion
of ASCT2 and amino acid (AA) depletion induced expression of SNAT2 (SLC38A2),
the activity of which was inhibited by AABA compounds. They also potently inhibited
isoleucine uptake via LAT1 (SLC7A5), a transporter that is upregulated in cancer cells
together with ASCT2. Inhibition of SNAT2 and LAT1 was confirmed by recombinant
expression in Xenopus laevis oocytes. The reported reduction of tumor growth in pre-
clinical models may be explained by a significant disruption of AA homeostasis.
Keywords: SLC1A5, SLC38A1, SLC38A2, SLC7A5, amino acid transport, homeostasis, glutaminolysis
INTRODUCTION
Rapid growth of cancer cells requires the maintenance of a homeostatic pool of cytosolic AAs
for protein biosynthesis and metabolic demands (Broer and Broer, 2017). Protein biosynthesis
is an essential function for cancer cell growth, using all 20 proteinogenic AAs, and is limiting
the overall growth of the tumor (Hosios et al., 2016). Membrane transporters are crucial to
facilitate the entry of AAs into cells and also for AA signaling. Microarray data pointed to
elevated expression levels of SLC1A5 (ASCT2) and SLC7A5 (LAT1) in many cancers (Fuchs
and Bode, 2005), which since has been confirmed in many studies and cell lines (reviewed in
Bhutia et al., 2015). To explain the abundance of ASCT2 and LAT1 in cancer cells, a model
was proposed in which glutamine enters cells through ASCT2 and is subsequently used as an
exchange substrate to import leucine among other essential AAs via LAT1 and to maintain
mTORC1 in an activated state (Nicklin et al., 2009). The model has been challenged because
ASCT2 deletion does not reduce mTORC1 signaling in several cell lines (Broer et al., 2016;
Cormerais et al., 2018). As a result, we proposed an alternate model, in which ASCT2 and
LAT1 play an important role in harmonizing AA pools, due to their rapid AA exchange
activity (Broer et al., 2016; Broer and Broer, 2017). Regardless of the role, ASCT2 has been
targeted by RNA-mediated silencing in a number of studies. Significant reduction of cell
growth was observed in Sloan-Kettering hepatoma cells (Fuchs et al., 2004). Similarly, reduced
Abbreviations: AA, amino acid; AABA, 2-amino-4-bis(aryloxybenzyl)aminobutanoic acids; DMEM, Dulbecco’s modified
Eagle’s medium.
Frontiers in Pharmacology | www.frontiersin.org 1 July 2018 | Volume 9 | Article 785
Bröer et al. Off-Target Effects by Novel ASCT2 Inhibitors
growth and tumor progression was reported in PC-3 prostate
cancer cells (Wang et al., 2015). van Geldermalsen et al. (2016)
reported reduction of cell growth in HCC1806 basal-like breast
cancer cells, but not in MCF-7 luminal cancer cells. ASCT2
knockdown also significantly reduced tumor size in HCC1806
xenografts. Hassanein et al. (2015) reported highly variable tumor
size in A549 lung cancer cell xenografts, with very large tumors
only occurring in cells containing ASCT2. When ASCT2 was
deleted in A549 and LS174T colon cancer cells, in vitro, cell
growth was reduced only in A549 cells, but xenograft tumor size
of both cell lines was reduced (Cormerais et al., 2018).
Pharmacological approaches to test the role of ASCT2 in
cancer cell growth have been hampered by the lack of specific
inhibitors. Several studies have used γ-glutamyl-p-nitroanilide
(GPNA) to examine involvement of ASCT2 in cancer cell growth
(e.g., Hassanein et al., 2013; Ren et al., 2015; Wang et al., 2015);
however, the glutamine analog blocks a variety of glutamine
transporters such as SNAT1, SNAT2 (Broer et al., 2016), and
LAT1 (Chiu et al., 2017). Thus, it is unclear whether the reduction
of growth observed in studies using GPNA is a result of ASCT2
inhibition. Due to the lack of specific inhibitors, it is often
difficult to precisely align the activity of individual transporters
with the uptake of radiolabeled substrates. However, inhibition
by N-methyl-aminoisobutyric acid (MeAIB) in non-epithelial
cells is a reliable indicator for the presence of SNAT1 and/or
SNAT2, together known as system A activity (Broer, 2014). LAT1
activity can now be identified using the specific high-affinity
inhibitor JPH203 (Wempe et al., 2012). A novel potentially
specific inhibitor of ASCT2 was published recently (Schulte et al.,
2016), which reduced tumor growth inmice in vivo (Schulte et al.,
2018) and appeared to be a potent blocker of ASCT2. The series of
compounds is based on AABA. In the earlier study (Schulte et al.,
2016), a derivative called compound 12 was identified as the most
potent inhibitor of ASCT2. In the in vivo experiments (Schulte
et al., 2018), a slightly different compound from the same series
was used, called V-9302. In this study, we used compound 12 and
V-9302 (Figures 1A,B), which were reported to inhibit human
ASCT2with an IC50 of 7–10μM(Schulte et al., 2016, 2018). Here,
we report that compound 12 and V-9302 do not inhibit ASCT2,
but rather block Sodium-neutral AA transporter 2 (SNAT2 and
SLC38A2) and the large neutral AA transporter 1 (LAT1 and
SLC7A5). This was observed in 143B osteosarcoma cells and
HCC1806 breast cancer cells and confirmed by recombinant
expression of SNAT1, SNAT2, ASCT2, and LAT1 in Xenopus
laevis oocytes. The combined block of SNAT2 and LAT1 is likely
to underlie the observed biological effects. A specific ASCT2
inhibitor remains to be identified.
MATERIALS AND METHODS
Custom Synthesis of 2-Amino-4-
Bis(aryloxybenzyl)aminobutanoic Acid
Compound 12 and V-9302
Synthesis was performed as described by Schulte et al. (2016). The
compounds were synthesized by Exclusive Chemistry, Obninsk,
Russia. Compound identity was verified by LC-MS and 1H-NMR
(Supplementary Figures S1, S2).
Animals
Holding of Xenopus laevis frogs (purchased from Nasco, Fort
Atkinson, WI, United States) and the surgical procedure to
remove parts of the ovary were approved by the Animal
experimentation ethics committee of the Australian National
University (Protocol A2017/36). All procedures were carried out
in accordance with the recommendations of the Australian code
for the care and use of animals for scientific purposes.
Cell Lines and Cell Culture
Human thymidine-kinase-negative osteosarcoma cells, 143B
(TK−) were a gift by Dr. David Tscharke (John Curtin
School of Medical Research, ANU), and human HCC1806
breast cancer cells were a gift by Dr. Jeff Holst (Centenary
Institute, Sydney, NSW, Australia). Both cell lines were either
cultured in DMEM/Ham’s F12 (Sigma 6124 supplemented
with 2-mM glutamine) or in BME medium (Thermo 21010)
supplemented with 10% dialyzed fetal bovine serum (FBS, Life
Technologies), non-essential AAs (Table 1), and 0.5-mM sodium
pyruvate at 37◦C in a humidified atmosphere of 5% CO2 in
air. For sub-culturing, cells were detached by trypsinization
(0.05 or 0.25% trypsin–EDTA, GIBCO). Cell counting was
performed using a Scepter cell counter (Millipore, United States)
or a hemocytometer. All complete cell culture media were
supplemented with 2-mM L-glutamine (GIBCO). Cell viability
after trypsinization was generally ≥95% as evaluated by trypan-
blue exclusion.
Genomic Mutation of the ASCT2 (Slc1a5)
Gene
A commercial CRISPR/Cas9 system was used (Sigma).
Generation of ASCT2ko 143B cells was described recently (Broer
et al., 2016), and the same method was used to mutate ASCT2
in HCC1806 cells. Briefly, the construct U6gRNA-pCMV-Cas9-
2A-GFP contains a 22-bp guide RNA (cctcgaagcagtcaacctcccg)
resulting in cleavage/repair of the Slc1a5 gene in exon 7. An
endotoxin-free preparation (Macherey and Nagel) of the plasmid
was used for transfection of HCC1806 cells maintained in
DMEM/Ham’s F12/10% FBS/2-mM glutamine. Cells were
seeded out in a 60-mm dish and grown until reaching 80%
confluence. Immediately before transfection, the cells were
replenished with fresh DMEM/HamF12/10% FCS/2 mM
glutamine. Plasmid DNA (4 μg) and 10-μl Lipofectamine
2000 (Invitrogen) were separately incubated in 500 μl of
Opti-MEM (Invitrogen) for 5 min at room temperature, before
combining them and incubating for a further 20 min at room
temperature to form complexes. The complexes were then
added drop-wise to the cells and placed in an incubator at
37◦C/5% CO2, followed by a media change after 6 h. After
48 h of expression, cells were trypsinized [0.25% Trypsin/EDTA
(Invitrogen)] and collected by centrifugation (500 × g)
followed by three washes in Dulbecco’s phosphate-buffered
saline supplemented with 5-mM glucose and 1% dialyzed
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FIGURE 1 | Inhibition of tumor cell growth by AABA. Structure of 2-amino-4-bis(aryloxybenzyl)aminobutanoic acids compound 12 (A) and V-9302 (B) as described
by Schulte et al. (2016, 2018). (C) The presence of ASCT2 in wild-type and genome-edited 143B cells was evaluated by western blotting of cell homogenates using
an ASCT2-specific antibody. (D) Growth of parental and ASCT2ko 143B cells was monitored using IncuCyte technology in the presence of increasing
concentrations of compound 12 (n = 12, cells were seeded from at least three different batches). (E) Reproducibility of cell growth assays in a well-to-well
comparison showing growth in DMEM/F12 supplemented with 2-mM glutamine and BME supplemented with 0.5-mM glutamine. Concentration of compound 12 is
indicated in the margin. (F) Growth of parental and ASCT2ko 143B cells was monitored using IncuCyte technology in the presence of increasing concentrations of
V-9302 (n = 10, cells were seeded from at least three different batches).
FBS (Sigma). Cells were then passed through a cell strainer
(70 μm, Corning), centrifuged, and suspended in PBS (pH
7.4) supplemented with 5-mM glucose and 1% dialyzed FBS.
Single cell sorting was performed using an ARIA II FACS
machine (FACS Facility Australian National University) with
GFP intensity set at two different levels. Single cells were
collected in 96-well plates containing DMEM/Ham’s F12/10%
FBS/2 mM glutamine and incubated for up to 3 weeks at
37◦C/5% CO2. Established clones were trypsinized and seeded
into 25-cm2 cell culture flasks (Corning) for further propagation.
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TABLE 1 | Amino acid composition of media used in this study (in mM).
Amino acid DMEM/F12 BME Physiological
(Sigma D6421) (Thermo 21010) concentrations#
Arg 0.702 0.099 0.032–0.11
Cys 0.1 0.05 0.003–0.095
His 0.15 0.051 0.039–0.123
Ile 0.416 0.198 0.036–0.107
Leu 0.45 0.198 0.068–0.183
Lys 0.5 0.199 0.103–0.255
Met 0.234 0.05 0.004–0.044
Phe 0.214 0.1 0.035–0.08
Thr 0.445 0.2 0.085–0.231
Trp 0.044 0.0196 0.029–0.077
Tyr 0.23 0.099 0.031–0.09
Val 0.452 0.2 0.136–0.309
Asp 0.05 0.005∗ <0.007
Gly 0.25 0.35∗ 0.126–0.49
Pro 0.15 0.25∗ 0.097–0.368
Ser 0.25 0.1∗ 0.063–0.187
Ala 0.05 0.5∗ 0.2–0.579
Asn 0.057 0.1∗ 0.037–0.092
Glu 0.05 0.1∗ 0.013–0.113
Gln variable variable 0.371–0.957
∗AAs added to the media at the final concentration indicated in the table.
#Physiological plasma concentration adult, fasting (Mayo Clinic, Quantitative AA-
Analysis). Glutamine was added to the media at the concentration indicated.
Inactivation of ASCT2 was verified by immunoblotting and
genomic sequencing.
Growth Assays
For growth assays, HCC1806 and 143B cells – derived from
at least three different cell batches – were seeded into 96-well
culture plates at a density of 4,000–5,000 cells per well and kept
in DMEM/Ham’s F12/10% FCS or in BME/10% dialyzed FCS
supplemented with 0.5 or 2-mM glutamine. Inhibitor (AABA)
was added at the concentrations indicated in the figures. Cell
proliferation was measured using an IncuCyte system (Essen
BioScience) over 54 h with a scan interval of 3 h. IncuCyte data
are shown as cell confluence (mean ± SEM) at set intervals.
Amino Acid Flux Assays
All uptake assays were performed in a water bath at 37◦C as
described by Deitmer et al. (2003) with some modifications.
Briefly, cells were grown to confluence in 35-mm cell culture
dishes and the media was replaced 12 h before the uptake assay.
For Na+-dependent transport, Hanks’ balanced salt solution
(136.6 mM NaCl, 5.4 mM KCl, 2.7 mM Na2HPO4, 1.3 mM
CaCl2, 0.5 mM MgCl2, 0.44 mM KH2PO4, 0.41 mM MgSO4,
5 mM HEPES, pH 7.5) supplemented with 5-mM glucose was
used. For Na+-independent transport, NaCl was substituted
with N-methyl-D-glucamine chloride (NMDG-Cl), and sodium
phosphate with potassium phosphate. L-[U 14C]glutamine
(1.85 MBq/mL, 9.26 GBq/mmol, PerkinElmer) and L-[U
14C]isoleucine (1.85 MBq/mL, 9.26 GBq/mmol, PerkinElmer)
were used at ∼2,000 dpm/nmol with unlabeled L-AA adjusted
to 100 μM final concentration. Transport rates were normalized
to cell-derived protein content measured by Bradford reagent
(Sigma). Uptake rates were expressed as mean (±SD) and
statistical differences were evaluated by ANOVA or T-test.
Preparation of Cell Homogenates and
Surface Biotinylation
Cells were grown to approximately 80% confluency on a 100-
mm cell culture dish in DMEM/F12/10% FCS 2-mM glutamine
before washing the monolayer gently thrice with ice-cold PBS
(pH 7.4). Cells were kept on ice at all times. To lyse the
cells, 500 μl of RIPA Lysis Buffer (Sigma) supplemented with
protease inhibitor Pefabloc EDTA-free (Roche) was added,
and the cells collected with a cell scraper. The lysate was
transferred to a reaction tube and incubated on ice for
15 min, before homogenization with an Omni Pro200 for
20 s. The samples were incubated on ice for an additional
15 min before centrifugation at 13,000 × g for 5 min
at 4◦C. The supernatant was collected and subjected to a
protein determination assay (Bradford Reagent, Sigma). Fifty
micrograms of the homogenate was loaded into each well of
a polyacrylamide gel (Invitrogen). After separation by PAGE,
proteins were transferred onto nitrocellulose membranes for
immunodetection.
For surface biotinylation, cells were grown in 60-mm dishes
and washed thrice in 5 ml modified PBS (supplemented with 1-
mM CaCl2 and 0.6-mMMgCl2, pH 8.0). Cells were then covered
with 2-ml 0.5 mg/ml EZ-link Sulfo-NHS-lc-Biotin (Thermo
Fisher Scientific) in modified PBS (pH 8.0) and incubated for
30 min at room temperature on a rotary shaker at low speed.
Biotinylation was terminated by washing thrice in modified
PBS supplemented with 100-mM glycine, pH 8.0. Cells were
scraped together, transferred to a 1.5-ml reaction tube and
lysed by addition of 1 ml 150 mM NaCl, 1% Triton X-100,
20 mM Tris–HCl, pH 7.5. The homogenate was incubated
on ice for 1.5 h to complete lysis. Subsequently, the lysate
was centrifuged at 13,000 × g in a table-top centrifuge for
10 min and the supernate was transferred to a new tube.
After protein determination, equal amounts of cell lysate
were added to 150-μl high-capacity streptavidin agarose beads
(Thermo). The beads were incubated overnight at 4◦C on a
rotary shaker before washing four times in lysis buffer. The
streptavidin-agarose slurry was mixed with protein sample buffer
and sample reducing reagent. After boiling for 5 min, 40-μl
samples were loaded onto a polyacrylamide gel. After separation,
proteins were transferred onto nitrocellulose membranes for
immunodetection.
SDS-PAGE and Western Blotting
To prepare protein samples for SDS-PAGE, 50–100 μg total
protein was mixed with 4× LDS sample buffer (Invitrogen),
10× reducing agent (Invitrogen), and made up to a final
volume of 20 μl using MilliQ water. Homogenate samples
were then incubated at 70◦C for 10 min before loading onto
the gel. Electrophoresis was performed using 4–12% Bis–Tris
polyacrylamide NuPAGER© gels (Invitrogen), electrophoresed
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TABLE 2 | Source of antibodies and dilution for western blotting.
Target Manufacturer Dilution
ASCT2 (SLC1A5) Cell Signaling Technology 1:3000, clone D7C12
SNAT1 (SLC38A1) Millipore 1:2000
SNAT2 (SLC38A2) Abcam 1:2000
Na+/K+-ATPase Abcam 1:7500
Actin Cell Signaling Technology 1:5000
Rabbit IgG (HRP conj) GE Healthcare 1:1000–1:10,000
Mouse IgG (HRP conj) Cell Signaling Technology 1:3000–1:5000
in an XCell SureLock R© Mini-Cell (Invitrogen) under reducing
conditions according to standard manufacturer procedures.
The SeeBlue Plus 2 pre-stained protein ladder (Invitrogen)
was used to estimate the apparent molecular weight of
proteins. Following SDS-PAGE, proteins were transferred onto
nitrocellulose membranes (GE Healthcare) using the Mini
Trans-Blot Electrophoretic Transfer Cell (Bio-Rad) according
to the standard protocols. Blots were blocked for 2 h at
room temperature (or overnight at 4◦C) in 50 ml 10% (w/v)
skim milk in PBS (pH 7.4) with 0.15% TWEEN 20 (PBS-
T). After washing three times in PBS-T for 10 min each,
the blots were incubated with the primary antibody for
2 h or overnight in 5-ml skim milk (2%, w/v) in PBS-T
at dilutions listed in Table 2. Excess primary antibody was
removed by washing three times with PBS-T. Blots were
incubated with 5 ml of diluted secondary antibody for 2 h.
After washing three times in PBS-T and a final rinse in PBS,
reactive bands were detected by enhanced chemiluminescence,
using Luminata Crescendo or Forte western HRP Substrate
(Millipore Merck). For re-probing, the same blots were
incubated for 30 min at 70◦C in 50-ml stripping buffer
(62.5 mM Tris–HCl (pH 6.8), 2% SDS, and 100 mM 2-
mercaptoethanol). Membranes were then washed three times
with PBS-T and blocked for 3 h using 10% (w/v) skim milk
in PBS-T before re-probing with next antibody as described
above.
Docking Studies
A homology model of human LAT1 was built based on the
apo outside open conformation (5J4I) of the E. coli arginine–
agmatine antiporter (Ilgu et al., 2016) an established prokaryotic
model of LAT1 (Palacin et al., 2016). The profile-based alignment
was generated using HHpred through the MPI bioinformatics
toolkit (Zimmermann et al., 2017). The alignment was then used
to generate a homology model through the Swiss Model server
(Waterhouse et al., 2018). Docking of V-9302 was performed
using the PyRX docking software (Dallakyan and Olson, 2015).
Oocyte Expression Systems and Flux
Experiments
Xenopus laevis oocytes were isolated and maintained as described
previously (Broer, 2003). Selected oocytes were injected with
10 ng of human ASCT2, human SNAT1, and human SNAT2 or
5 ng each of rat LAT1 and human 4F2hc cRNA and were used as
described previously (Broer et al., 1999).
RESULTS
Effect of AABA on Cell Growth
The structure of the two AABA derivatives evaluated in this
study, compound 12 and V-9302, are depicted in Figures 1A,B,
respectively. To study the role of ASCT2 in AA homeostasis, we
have recently generated a 143B osteosarcoma cell line lacking
ASCT2 using CrispR/Cas9-mediated genome editing (Broer
et al., 2016; Figure 1C). The cell line was chosen to study the role
of AA transporters in AA homeostasis due to its relatively simple
expression profile of AA transporters. In addition, it can be used
to test the specificity of ASCT2 inhibitors. To test the specificity
of compound 12, we determined the growth rate of ASCT2
expressing parental cells and ASCT2ko cells (Figures 1D,E).
To our surprise, growth was inhibited by compound 12 in
both cell lines with equal efficacy (IC50 = 26 and 24 μM for
parental and ASCT2ko, respectively, difference not significant),
suggesting that the target of the compound was not ASCT2.
This was confirmed using the related compound V-9302, which
if anything inhibited ASCT2ko cells more effectively than the
ASCT2 expressing parental cells (Figure 1F). To exclude that the
inhibitor may not be effective at the high AA concentrations of
DMEM/F12 medium (containing 2-mM glutamine), we repeated
the experiment with compound 12 in BMEmediumwith 0.5-mM
glutamine, which is close to in vivo conditions (Figures 1D,E).
The reduced competition by medium AAs improved the efficacy
of the inhibitor slightly, but again no difference was observed
between ASCT2 expressing and ASCT2ko cells (IC50 = 20 and
19 μM for parental and ASCT2ko, respectively, difference not
significant).
Effect of Compound 12 on Glutamine
Transport
ASCT2 is highly expressed in almost any cancer cell line
and mediates a large fraction of glutamine uptake (Fuchs and
Bode, 2005; Broer and Broer, 2017; Cormerais et al., 2018). To
investigate the target of compound 12 further, we determined
its effect on glutamine transport at a concentration of 100 μM,
which is 5× the IC50 to inhibit growth (Figure 1D). In 143B
cells, ASCT2 mediates about 50% of glutamine uptake at a
concentration of 100 μM (Broer et al., 2016; also compare
parental and ASCT2ko glutamine transport in Figure 2A).
However, only a small non-significant fraction of glutamine
uptake was inhibited by compound 12 in ASCT2 expressing
parental 143B cells (Figure 2A, +AA panel, blue and yellow
bars). In ASCT2ko cells, by contrast, the remaining glutamine
uptake was strongly inhibited by compound 12 (Figure 2A,+AA
panel, brown and green bars). We have recently shown that
deletion of ASCT2 generates an AA stress response in 143B
cells, which results in the upregulation of SNAT1 (SLC38A1)
and SNAT2 (SLC38A2), collectively known as system A activity
(Broer et al., 2016). Because SNAT1, SNAT2, and ASCT2 have
similar substrate specificity, upregulation of these transporters
can compensate for the lack of ASCT2 and it is often difficult to
discriminate the individual transporters. To further investigate
whether compound 12 inhibits SNAT1 and SNAT2 activity,
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FIGURE 2 | Inhibition of glutamine transport by AABA in wild-type and ASCT2ko cells. (A) Uptake of [14C]glutamine (100 μM) was measured in 143B cells [parental
(wt) and ASCT2ko] in the presence or absence of 100 μM compound 12. Before transport, cells were kept in DMEM/F12 medium supplemented with 10% FCS
(+AA) or in Hank’s buffered salts solution supplemented with 5-mM glucose and 1% dialyzed FCS (–AA) for 12 h [parental (wt) n = 5 and ASCT2ko n = 9 for each
condition]. p-Values are indicated in the figure. (B) 143B cells and HCC1806 cells were incubated as in A and used for surface biotinylation and subsequent
detection of glutamine transporters by immunoblotting. Na+, K+-ATPase was used as a loading control; the SNAT2-specific band is indicated by an asterisk (*)
(n = 3). (C) Detection of ASCT2 in cell homogenates of parental and genome edited HCC1806 triple-negative breast cancer cells. Actin was used as a loading
control (n = 5). (D) Uptake of [14C]glutamine (100 μM) was measured in HCC1806 cells [parental (wt) and ASCT2ko] in the presence or absence of 100 μM
compound 12. Before transport, cells were kept in DMEM/F12 medium supplemented with 10% FCS (+AA) or in Hank’s buffered salts solution supplemented with
5-mM glucose and 1% dialyzed FCS (–AA) for 12 h (parental n = 5 and ASCT2ko n = 5 for each condition). p-Values are indicated in the figure.
we incubated cells overnight in Hank’s buffered salts solution
[pH, 7.5 supplemented with 5-mM glucose and 1% dialyzed
FCS, no AAs (−AA in Figure 2)], a maneuver that increases
system A activity. We confirmed by surface biotinylation and
western blotting that this treatment strongly increased the
surface expression of SNAT1 and SNAT2, while ASCT2 remained
unaffected (Figure 2B). The corresponding additional transport
activity was completely abolished by addition of compound 12
in parental cells and in ASCT2ko cells (Figure 2A, +AA panel).
Notably, induction of system A activity was more pronounced in
ASCT2ko cells than in parental cells.
To substantiate our observation, we deleted ASCT2 in
HCC1806 triple-negative breast cancer cells, a cell line also
used by Schulte et al. (2018; Figure 2C). In contrast to 143B
cells which are not sensitive to ASCT2 deletion (Broer et al.,
2016), HCC1806 cells were reported to be sensitive to ASCT2
silencing (van Geldermalsen et al., 2016). Nevertheless, the
ASCT2ko cells could be grown in DMEM/F12 medium. Very
similar to 143B cells, glutamine uptake in ASCT2 expressing
HCC1806 cells was not sensitive to inhibition by compound
12, but the remaining glutamine uptake in ASCT2ko cells
was sensitive to the inhibitor (Figure 2D, panel +AA). AA
depletion (Figure 2D, −AA) induced additional glutamine
uptake capacity in parental cells, which was also sensitive
to inhibition by compound 12. In ASCT2ko cells, glutamine
transport did not increase much further upon AA depletion,
but remained sensitive to compound 12 (Figure 2D). These
results suggest that compound 12 does not target ASCT2 as
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FIGURE 3 | Inhibition of system A and LAT1 activity by AABA. (A) Uptake of [14C]glutamine (100 μM) was measured in parental (wt) or ASCT2ko 143B cells in the
presence (n = 9 each group) or absence of 100 μM compound 12 (n = 9 each group) or 10-mM MeAIB (n = 6). Before transport, cells were kept in DMEM/F12
medium supplemented with 10% FCS (+AA) or in Hank’s buffered salts solution plus 5-mM glucose and 1% dialyzed FCS (–AA) for 12 h. n.s. difference not
significant. p-Values for significant differences are shown in the figure. (B) Uptake of [14C]isoleucine (100 μM) was measured in Na+-free buffer in 143B cells (n = 6),
in the presence (n = 6) or absence (n = 6) of 100 μM compound 12 or 2 μM JPH203 (n = 6) n.s. difference not significant. (C) Uptake of [14C]glutamine was
measured as in A, but V-9302 was used instead of compound 12 (n = 3, p-values indicated in the figure). (D) Uptake of [14C]isoleucine was measured as in B, but
V-9302 was used instead of compound 12 (n = 3, p-values indicated in the figure).
suggested previously (Schulte et al., 2016), but may inhibit system
A activity.
Inhibition of System A and L by AABA
To investigate whether compound 12 inhibited system A
activity, we compared it to MeAIB a known low-affinity
inhibitor of system A activity, which is mediated by SNAT1
and SNAT2 (Christensen et al., 1965; Broer, 2014). Consistent
with compound 12 being a system A inhibitor, the fraction
of glutamine transport inhibited by MeAIB closely matched
the fraction inhibited by compound 12, particularly in parental
cells (Figure 3A, compare yellow and brown bars). Inhibition
of glutamine transport was also similar after AA depletion,
thereby resulting in an increased fraction of glutamine transport
mediated by SNAT1/2. Small differences between MeAIB and
compound 12 were observed in ASCT2ko cells, pointing to the
upregulation of additional glutamine transporters (Figure 3A).
Schulte et al. (2018) reported that leucine transport was
inhibited by V-9302, although with lower potency than glutamine
transport. We could reproduce this observation by showing
potent inhibition of Na+-independent transport of isoleucine
by compound 12 (Figure 3B). The inhibition was overlapping
with the inhibition of isoleucine transport by the LAT1 specific
inhibitor JPH203 (Wempe et al., 2012), demonstrating LAT1 as a
second target. To test whether V-9302 (Figure 1B), which was
shown to inhibit tumor growth in vivo (Schulte et al., 2018),
has the same targets, we repeated the experiments. Consistent
with the results shown in Figure 3A for compound 12, V-9302
inhibited only a small fraction of glutamine uptake in wild-
type cells that was similar to the fraction inhibited by MeAIB
(Figure 3C, compare orange and brown bars). AA depletion
(−AA) increased the fraction of MeAIB and V-9302 sensitive
glutamine uptake consistent with induction of SNAT1 and 2. In
ASCT2ko cells, V-9302 and MeAIB inhibited a larger fraction
of glutamine uptake than in parental cells, due to induction of
SNAT1 and 2. Some differences between V-9302 and MeAIB can
be observed in Figure 3C, which may be the result of changes in
LAT1 activity. As reported, V-9302 inhibited isoleucine transport
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FIGURE 4 | Evaluation of inhibitor specificity. (A) Transporters hSNAT1, hSNAT2, hASCT2, and h4F2hc/rLAT1 were expressed in Xenopus laevis oocytes. Transport
experiments were performed 4–7 days after injection of the corresponding cRNAs. Glutamine uptake was used to measure hSNAT1, hSNAT2, and hASCT2 activity,
while isoleucine transport was used to measure h4F2hc/rLAT1 activity. Uptake was measured in the presence or absence of inhibitors as indicated (n = 8 for each
transporter) in three batches of oocytes. (B) A homology model of human LAT1 was generated after alignment with the E. coli arginine–agmatine antiporter (PDB
5J4I). Docking of V-9302 was performed using PyRX. One of several energetically favorable poses is shown. (C) Delineation of glutamine transport pathways in
143B osteosarcoma cells. The contributions of SNAT1, SNAT2, ASCT2, and LAT1 were deduced using combinations of inhibitors (n = 6). Groups that were different
(p < 0.001) have different letter labeling.
via LAT1, although it was performing less well than JPH203
(Figure 3D).
The experiments thus far established that AABA compounds
are potent inhibitors of several AA transporters in two different
cell lines. To evaluate the effect on individual transporters we
used recombinant expression in Xenopus laevis oocytes, a system
widely used to express membrane transporters (Figure 4A).
Consistent with our cell line studies, we found that compound
12 and V-9302 inhibited SNAT2 and LAT1, but not ASCT2
or SNAT1 (Figure 4A). In order to understand the potent
inhibition of LAT1, we performed molecular docking studies
on a homology model of LAT1 based on an alignment with
the arginine–agmatine antiporter from E. coli. This transporter
is an established model for LAT1 (Palacin et al., 2016) and
its structure is available in the outside-open conformation
(Protein data bank structure 5J4I; Ilgu et al., 2016), which
is the relevant conformation for inhibitor binding (Broer,
2018). Several binding poses with similar binding energies
were identified, demonstrating a tight fit of the inhibitor to
the vestibule and substrate binding site of the outside open
transporter (Figure 4B).
In most cancer cells, glutamine uptake is mediated by
contributions from ASCT2, SNAT1, SNAT2, and LAT1 (Broer
and Broer, 2017). A comprehensive understanding of the
inhibitory properties of compound 12 and V-9302 should allow
a seamless delineation of these pathways. This is shown in
Figure 4C using 143B wild-type cells that were incubated in AA-
free media to induce SNAT2. MeAIB was used to inhibit SNAT1
and SNAT2 together (known as systemA activity). Compound 12
and V9302 inhibited about 50% of system A activity, attributing
the other 50% to SNAT1. Combining MeAIB with V9302 or
compound 12, showed a slightly stronger depression of glutamine
uptake than MeAIB alone, an activity which can be attributed to
LAT1. LAT1 has a low affinity for glutamine (Napolitano et al.,
2015) and therefore its contribution is rather small consistent
with our previous data (Broer et al., 2016). The fraction of
glutamine uptake mediated by ASCT2 remained resistant to any
of the inhibitors.
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FIGURE 5 | A model of amino acid homeostasis in cancer cells. The physiological role of SNAT1 is to accumulate non-essential amino acids in the cytosol (loader).
These are used as exchange substrates to bring the remaining neutral amino acids into the cytosol via exchangers ASCT2 and LAT1, thus harmonizing amino acid
pools. Blockade of LAT1 causes a rescue response resulting in the induction of SNAT2. Block of these two transporters impairs accumulation and harmonization of
amino acid pools in cancer cells and also negates the rescue response.
DISCUSSION
Despite the urgent need for a high-affinity, specific ASCT2
inhibitor to study the role of AA transporters in cancer cell
growth, our results demonstrate that neither compound 12 nor
V-9302 are fulfilling this role. The strong effect of V-9302 on
tumor cell growth is consistent with the combined inhibition
of SNAT2 and LAT1, but may involve additional targets. We
have recently proposed a unified model of AA homeostasis
(Broer et al., 2016; Figure 5) in which SNAT1 serves as an
AA “loader” that accumulates a small group of non-essential
neutral AAs into cancer cells. These serve as exchange substrates
for AA antiporters such as ASCT2 and LAT1 (Utsunomiya-
Tate et al., 1996; Meier et al., 2002; Pingitore et al., 2013;
Napolitano et al., 2015), which bring essential AAs [threonine (via
ASCT2), and leucine, isoleucine, valine, phenylalanine, tyrosine,
tryptophan, and histidine (via LAT1)] into the cells at the
expense of non-essential AAs, particularly glutamine. We termed
these antiporters “harmonizers” to emphasize their role in AA
homeostasis and the maintenance of significant pools of all
20 proteinogenic AAs. Under conditions of nutrient limitation,
cancer cells exert an AA stress response, which results in the
upregulation of SNAT2 as shown in this study and previously
(Lopez-Fontanals et al., 2003; Palii et al., 2006). Moreover, it
results in the induction of anabolic pathways for non-essential
AAs (Balasubramanian et al., 2013). The block of LAT1 alone by
V-9302 is sufficient to disrupt AA homeostasis, due its role in
the acquisition of essential AAs. The rescue response, however, is
blunted by the concurrent inhibition of SNAT2. The efficacy of V-
9302 is likely to be a result of inhibition of the harmonizer LAT1
in combination with the “rescue” transporter SNAT2. However,
we cannot exclude additional targets of this compound. Overall,
our results explain that potent disruption of AA homeostasis in
cancer cells can be used to block tumor cell growth.
In two cancer cell lines (143B and HCC1806), we have shown
that ASCT2 can be deleted without compromising cell growth
in vitro (data presented here and in Broer et al., 2016). This was
also confirmed in another study using LS174T colon cancer and
A549 lung cancer cells (Cormerais et al., 2018). These results
suggest that therapeutic approaches targeting only one particular
AA transporter are unlikely to succeed. However, disturbing
AA homeostasis more drastically remains a promising approach
in cancer therapy. Essential AAs must be acquired by cancer
cells through membrane transport. This is illustrated by the
deletion of CD98 in LS174T cells, a surface protein required
for the trafficking of a number of AA transporters, such as
LAT1, LAT2, and xCT to the cell surface (Cormerais et al.,
2016). Surprisingly, the small residual uptake activity mediated
by LAT1 in the absence of CD98 (about 10%) appeared to be
sufficient to sustain cell growth. Complete block by addition
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of the LAT1-specific inhibitor JPH203 or deletion of LAT1 did
reduce cell growth dramatically. This suggests that cancer cell
lines have significant reserve capacity for AA uptake, the uptake
of which needs to be inhibited completely to block cell growth.
This was confirmed in a first clinical trial using JPH203, in which
only patients receiving higher doses of the drug achieved longer
survival (Okano et al., 2018). The in vivo efficacy of V-9302
suggests that it causes sufficient disruption to AA homeostasis,
potentially in combination with other effects, to be a promising
candidate for cancer therapy, but its actions cannot be explained
by inhibition of ASCT2.
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